Skye Bioscience (SKYE)
(Delayed Data from NSDQ)
$3.89 USD
+0.10 (2.64%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $3.92 +0.03 (0.77%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SKYE 3.89 +0.10(2.64%)
Will SKYE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SKYE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SKYE
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
SKYE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for SKYE
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August ...
Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing
JMP Securities Reiterates Market Outperform Rating for Skye Bioscience (SKYE) | SKYE Stock News
Citizens JMP Sticks to Their Buy Rating for Skye Bioscience (SKYE)
Skye (SKYE) Explores Nimacimab's Role in Obesity Treatment at Evercore Event | SKYE Stock News